基础胰岛素的临床药效学评价
摘要
①葡萄糖钳夹试验显示：甘精胰岛素葡萄糖输注速率曲线下面积大于地特胰岛素和NPH，且具有统计学差异．但三者在降低HbA1c和空腹血糖方面无显著性差异。②地特胰岛素的体重增加作用明显弱于甘精胰岛素。
出处
《药品评价》
CAS
2011年第15期22-25,共4页
Drug Evaluation
参考文献18
-
1Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levds and insulin secretion during intravenous glucose tolerance tests[J]. J Clin Endocrinol Metab, 1976, 42(2): 222-229.
-
2Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine in comparison with those of NPH insulin and placebo[J]. Diabetes Care, 2000, 23(5): 644-649.
-
3Rosenstock J, Park G, Zimmerman J. Basal insulin glargine versus NPH insulin in patients with type 1 diabetes on multiple daffy insulin regimens[J]. Diabetes Care, 2000, 23(8): 1137-1142.
-
4Soran H, Younis N. Insulin detemir: a new basal insulin analogue[J]. Diabetes Obes Metab, 2006, 8(1): 26-30.
-
5Kaplan W, Rodriguez LM, Smith OE, et al. Effects of mixing glargine and short-acting insulin analogue on glucose control[J], Diabetes Care, 2004, 27(1 I): 2739-2740.
-
6Colino E, Lopez-C M, Golmayo L, et al. Therapy with insulin glargine in toddlers, children and adolescents with type I diabetes[J]. Diabetes Res Clin Pract, 2005, (1): 1-7.
-
7Salemyr J, Bang P, Ortqvist E. Lower HbA1C, after 1 year, in children with type 1 diabetes treated with insulin glargine vs. NPH insulin from diagnosis: a retrospective study[Jl. Pediatr Diabetes, 2011, Mar 28. [Epub ahead of print].
-
8Rosenstock J, Schwartz SL, Clark CM, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine and NPH insulin[J]. Diabetes Care, 2001,24(4): 631-636.
-
9潘长玉,陆菊明,杨文英,郭立新,纪立农,刘志民,胡仁明,王长江,陈丽,闫胜利,林丽香,童南伟,李红,姚晨.随机、开放、低精蛋白锌胰岛素注射液平行对照,联合控释格列吡嗪评价重组甘精胰岛素注射液治疗口服降糖药控制不佳的2型糖尿病患者的有效性和安全性[J].中国药物应用与监测,2006,3(5):1-7. 被引量：6
-
10Eliaschewitz FG, Calvo C, Valbuena H, et al, Therapy in type 2 diabetes: insulin glargine vs, NPH insulin both in combination with glimepiride[J]. Arch Med Res, 2006, 37(4): 495-501.
二级参考文献10
-
1[1]UK Prospective Diabetes Study (UKPDS)Group.Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[J].Lancet,1998,352:837.
-
2[2]Stratton IM,Adler AI,Neil HA,et al.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study[J].BMJ,2000,321:405.
-
3[3]UK Prospective Diabetes Study Group.UK prospective diabetes study 16.Overview of 6 years'therapy of type Ⅱ diabetes:a progressive disease[J].Diabetes,1995,44:1249.
-
4[4]Yki-Jarvinen H,Kauppila M,Kujansuu E,et al.Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus[J].N Engl J Med,1992,327:1426.
-
5[5]Yki-Jarvinen H,Dressler A,Ziemen M.Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes[J].Diabetes Care,2000,23:1130.
-
6[6]Fritsche A,Schweitzer MA,Haring HU.Glimepiride combined with morning insulin glargine,bedtime neutral protamine hagedorn insulin,or bedtime insulin glargine in patients with type 2 diabetes:a randomized,controlled trial[J].Ann Intern Med,2003,138:952.
-
7[7]Turner RC,Cull CA,Frighi V,et al.Glycemic control with diet,sulfonylurea,metformin,or insulin in patients with type 2 diabetes mellitus:progressive requirementf or multiple therapies (U KPDS 49)[J].JAMA,1999,281:2005.
-
8[8]Riddle MC,Rosenstock J,Gerich J.The treat-to-target trial:randomized ad2 dition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients[J].Diabetes Care,2003,26:3080.
-
9[9]Gillies PS,Figgitt DP,Lamb HM.Insulin glargine[J].Drugs,2000,59:253.
-
10[10]Rosenstock J,Donley DW,Schwartz SL,et al.Basal insulin therapy in type 2 diabetes:28-week comparison of insulin glargine (HOE 901)and NPH insulin[J].Diabetes Care,2001,24:631.
共引文献5
-
1吴岩.甘精胰岛素和诺和灵N治疗2型糖尿病体会[J].医学理论与实践,2009,22(9):1074-1075. 被引量：2
-
2穆媛,宋春青.重组甘精胰岛素、NPH胰岛素治疗2型糖尿病100例体会[J].吉林医学,2011,32(16):3252-3253.
-
3胡雄峰.甘精胰岛素联合格列吡嗪治疗2型糖尿病的临床效果分析[J].中外医学研究,2012,10(7):16-17. 被引量：4
-
4姚丹,程时杰.甘精胰岛素与诺和灵N治疗2型糖尿病的治疗效果比较[J].医学与社会,2015,28(B05):174-174.
-
5易琼.甘精胰岛素联合格列吡嗪治疗2型糖尿病70例疗效观察[J].大家健康（学术版）,2013(20):168-168.
-
1Heise T,Pieber TR,李翔（编译）.趋于无峰、可重复的长效胰岛素——基于葡萄糖钳夹试验的基础胰岛素类似物评价[J].药品评价,2008,5(10):436-437. 被引量：1
-
2李刚,丛丽,殷娜,李强,王薇,张巾超.胰岛素和β肾上腺素受体激动剂对大鼠脂联素分泌和表达的影响[J].中华内分泌代谢杂志,2011,27(1):62-65. 被引量：1
-
3刘敬珍,赵亚芝,李萍,马博清.高胰岛素-正葡萄糖钳夹技术的护理[J].护理实践与研究,2010,7(15):39-41. 被引量：4
-
4谭惠文,王椿,刘瑶霞,喻红玲,张祥迅,冯萍,余叶蓉.短效重组人胰岛素在人体内的药动学及药效学研究[J].华西药学杂志,2011,26(5):407-410. 被引量：2
-
5杨光,李春霖,田慧,程时武,李一君,程晓玲,方福生.高胰岛素-正葡萄糖钳夹技术在不同人群中的建立条件比较[J].中华医学杂志,2012,92(34):2410-2414. 被引量：6
